Price (delayed)
$3.6
Market cap
$592.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$595.18M
Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management
There are no recent dividends present for SVRA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.